Macular Degeneration Foundation

Category: Basic Research


Promising Update on APL-2 for Dry AMD

Statistically Significant Slowing of Disease Progression Seen at 12 Months APL-2 is a synthetic peptide which shuts down the complement activation system responsible for local inflammation, tissue damage (as in dry AMD) and the resulting blood vessel growth (angiogenesis in…

Read More

New Biomarker for AMD

by Adam Pope 1/23/19 Researchers from the University of Alabama at Birmingham Department of Ophthalmology and Visual Sciences, along with collaborators from the University of Iowa, have discovered a genetic biomarker that is associated with age-related macular degeneration and delayed rod-mediated…

Read More

Genentech’s Faricimab for Wet AMD May Extend Time Between Injections

Genentech has announced positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD). According to Sandra Horning, M.D., chief medical officer and head of Global…

Read More